Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A phase 2 trial found that oral vitamin C (1,000 mg/day) is safe and biologically active in patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies. While it didn't hit the primary endpoint of reducing clonal growth rate, it led to fewer serious adverse events and significantly longer overall survival compared to placebo. Researchers say a larger study is needed before clinical recommendations can be made.
A new phase 2 randomized, double-blind, placebo-controlled trial published in Cancer suggests that oral vitamin C may offer meaningful benefits for patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies — two early-stage blood disorders that can progress to more serious conditions like leukemia.
The trial, led by researchers at Copenhagen University Hospital-Rigshospitalet in Denmark, enrolled 109 adults not currently receiving anticancer therapy. Participants received either 1,000 mg/day of oral vitamin C or a placebo for 12 months. While vitamin C didn't significantly reduce the primary endpoint of median clonal growth rate, several secondary outcomes told a more encouraging story — including differences in inflammatory cytokine trajectories and a notably lower rate of serious adverse events in the vitamin C group.
By the Numbers:
Why it matters: These findings hint that a simple, low-cost supplement could one day play a role in managing early blood disorders — but researchers caution that a larger trial is needed before any clinical recommendations can be made.
